retatrutide for obesity VisualAbstract: reduces body weight by 17.5% in patients with Retatrutide: A Multi-Receptor Approach to

Clarifying expectations helps your provider guide you appropriately and set realistic timelines

What to know about retatrutide

In fact, most studies suggest that function improves with significant weight loss

You bought a GLP-1 program to get your life back, not to spend the summer hiding from your own backyard

A Multi-Receptor Agonist for Advanced Metabolic Research Retatrutide Peptide Canada is a next-generation investigational peptide that acts as a triple agonist of the GLP-1, GIP, and glucagon receptors

Andrew Stokes, associate professor of global health, and a team of researchers from the School of Public Health will seek clarity on the population health effects of GLP-1 drugs with a new grant from the Robert Wood Johnson Foundation